For Immediate ReleaseAugust 3, 2021

Sumitomo Chemical Reports
Consolidated Financial Results
For the Three Months Ended June 30, 2021
For the first quarter ended on June 30, 2021, the Sumitomo Chemical Group reported
consolidated sales revenue of ¥639.0 billion, an increase of ¥138.8 billion year on year,
core operating income* of ¥61.7 billion, operating income of ¥58.3 billion, and net
income attributable to owners of the parent of ¥35.7 billion; all higher than the resultsfrom the same period of the previous year.
*Core operating income is a gain and loss concept, reflecting recurring earning
capacity, and deducts gains and losses incurred by non-recurring factors fromoperating income. It includes the share of profit from investments accounted for using
the equity method.
The financial results by business segment for the first quarter are as follows:
Petrochemicals & Plastics
Shipments and market prices of petrochemical products, synthetic resins andsynthetic fibers performed well.Thereby sales revenue increased by ¥91.3 billion to¥199.5 billion and core operating income recovered by ¥43.7 billion, to ¥23.8 billion,
compared with the same period of the previous year, when the shipment volumes
decreased due to the periodic shutdown maintenance for Rabigh Refining andPetrochemical Company, our equity method investee, and due to the impact of theCOVID-19 pandemic, mainly on demand for automotive use.
Energy & Functional Materials
Shipments of separators for lithium-ion secondary batteries performed well. Market
prices for aluminum and for the metal raw materials for cathode materials increased,
resulting in higher selling prices. For the same period of previous year, shipments
were lower, mainly for automotive use, due to the COVID-19 pandemic. As a result,sales revenue increased by ¥26.0 billion from the same period of previous year, to¥74.4 billion. Core operating income increased by ¥4.7 billion from the same period ofprevious year, to ¥6.7 billion.



IT-related Chemicals
Shipments of processing materials for semiconductors (including high purity
chemicals and photoresists) increased, driven by growing demand for these items.
Shipments of materials for display applications increased in the face of stay-at-homedemand and telework demand. As a result, sales revenue increased by ¥5.4 billion
from the same period of previous year, to ¥109.3 billion, and core operating income
increased by ¥3.6 billion from the same period of previous year, to ¥13.5 billion.
Health & Crop Sciences
Shipments of crop protection products in North America, South America and India
performed well. Market prices of methionine (feed additives) increased from the same
period of the previous year. As a result, sales revenue increased by ¥14.2 billion fromthe same period of previous year, to ¥103.1 billion. Core operating income increasedby ¥6.7 billion from the same period of previous year, to ¥10.3 billion.
Pharmaceuticals
In North America, Orgovyx™ (therapeutic agent for advanced prostate cancer), which
was launched in the previous fiscal year, and Gemtesa® (therapeutic agent for
overactive bladder) and Myfembree® (therapeutic agent for uterine fibroids), which
commenced sales this quarter, contributed to the sales revenue. However, declines insales of Brovana® (therapeutic agent for chronic obstructive pulmonary disease)
caused by the expiration of the exclusive marketing period, and Latuda® (atypicalantipsychotic agent) affected by an increase in shipments in the second half of theprevious fiscal year caused a negative impact. In addition, in Japan, sales revenues
were adversely affected by national drug price revisions. As a result, sales revenue
decreased by ¥1.6 billion from the same period of the previous year, to ¥139.2 billion.
Core operating income decreased by ¥14.9 billion from the previous year, to ¥9.6billion. The reason for the decline as well as lower sales revenue was the increase inselling, general and administrative expenses due to the start of full-scale marketing
activities by subsidiaries of Sumitovant Biopharma Limited.

Others
In addition to the above five segments, the Sumitomo Chemical Group supplies
electric power and steam, designs chemical plants and supervises the constructionof those facilities, provides transportation and warehousing, and conducts physicalproperty analysis and environmental analysis. Sales revenue of these businesses
increased by ¥3.4 billion from the same period of previous year, to ¥13.6 billion, andcore operating income increased by ¥0.4 billion from the same period of previousyear, to ¥2.7 billion.

Summary of Consolidated Results(1) Results of Operations:
Sales revenue
Core operating income(Share of profit of investments
accounted for using the equity method)
Operating income
Income before taxes
Net income
Net income attributable tonon-controlling interests
Net income attributable toowners of the parent

Net income per 1,000 shares

Comprehensive income(3 Months ended
June 30, 2021
Yen (Millions)
USD (Thousands)*
638,979
5,778,432
61,664
557,642
14,742 )(133,315 )3 Months ended
June 30, 2020
Yen (Millions)500,188
19,862((13,306) )58,34456,69338,884

527,618
512,688351,637

18,467
13,578
1,371

3,225

29,164

8,712

35,659322,472(7,341)

Yen
21,810

USD*
197

Yen(4,490)

Yen (Millions)
39,232

USD (Thousands)*
354,784

Yen (Millions)(3,003)As of June 30, 2021
Yen (Millions)
USD (Thousands)*
4,093,065
37,014,514
1,503,702
13,598,318

As of March 31, 2021
Yen (Millions)
3,990,254
1,482,119

3 Months ended
June 30, 2021
Yen (Millions)
USD (Thousands)*
4,690
42,413(41,274)(373,250)
41,457374,905
366,457
3,313,954

3 Months ended
June 30, 2020
Yen (Millions)
55,587(44,168)
126,598
329,698

3 Months ended
June 30, 2021
Yen (Millions)
USD (Thousands)*

3 Months ended
June 30, 2020
Yen (Millions)䚷(2) Financial Position:
Total assets
Total equity(3) Cash Flows:
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Cash and cash equivalents at end of period(4) Results of Operations by䚷䚷䚷Business Segment:
Sales revenue
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersCore operating income
Petrochemicals & Plastics
Energy & Functional Materials
IT-related Chemicals
Health & Crop Sciences
Pharmaceuticals
OthersAdjustments

199,532
74,385109,266
103,066
139,161
13,569638,979

1,804,413
672,680
988,117932,049
1,258,464
122,709
5,778,432

108,243
48,345
103,845
88,851
140,766
10,138500,188

23,822
6,710
13,48010,283
9,648
2,747(5,026)
61,664215,428
60,680121,903
92,991
87,24924,842(45,451)557,642(19,850)
1,978
9,855
3,550
24,531
2,374(2,576)
19,862(Note)䚷 *U.S. dollar amounts are translated from yen, for convenience only, at the rate ofࠉ¥110.58 = $1 prevailing on June 30, 2021.
䚷